I know that on the odd occasion that NEU has missed some timelines (by not very much however), but essentially this is a company that has been brilliantly managed and had delivered on virtually every promise they've made in the 10+ years I've been invested.
NEU couldn't be better set up than to be in a position where multiple propositions are going to be put to them in the next 12 months.
I suspect that I'm one of many extremely satisfied and excited investors.
- Forums
- ASX - By Stock
- NEU
- Ann: Neuren submits IND & first patients complete Phase 2 trials
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.36%
!
$13.03

Ann: Neuren submits IND & first patients complete Phase 2 trials, page-15
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.03 |
Change
0.175(1.36%) |
Mkt cap ! $1.626B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $5.929M | 452.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
41 | 1405 | $13.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.03 | 504 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
36 | 1160 | 13.020 |
29 | 6062 | 13.010 |
26 | 8223 | 13.000 |
5 | 1465 | 12.990 |
5 | 3301 | 12.980 |
Price($) | Vol. | No. |
---|---|---|
13.030 | 486 | 12 |
13.040 | 2283 | 23 |
13.050 | 2031 | 22 |
13.060 | 2370 | 10 |
13.070 | 1534 | 6 |
Last trade - 15.30pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online